Loading of doxorubicin on poly(methyl methacrylate-co-methacrylic acid) nanoparticles and release study

Abstract

Nanoparticles (NP) of 12.7 nm in diameter of the poly(methyl methacrylate (MMA)-co-methacrylic acid (MAA)) copolymer were prepared. 13 C-NMR results showed a MMA:MAA molar ratio of 0.64:0.36 in the copolymer, which is similar to the poly(MMA-co-MAA) commercially known as the FDA approved Eudragit S100 (0.67:0.33). The NP prepared in this study were loaded at pH 5 with varying amounts (from 0.54 to 6.91%) of doxorubicin (DOX), an antineoplastic drug. 1 H-NMR results indicated the electrostatic interactions between the ionized carboxylic groups of the MAA units in the copolymer and the proton of the glycosidic amine in DOX. Measurements by QLS and TEM indicated that the loading destabilizes the NP, and that for increase stability, they aggregate in a reversible way, forming aggregates with a diameter up to 99.5 nm at a DOX load of 6.91%. The analysis of drug release data at pH 7.4 showed that loaded NP with at least 4.38% DOX release the drug very slowly and follows the Higuchi model; the former suggests that they could remain for long periods in the bloodstream to reach and destroy cancer cells.

Cell-Penetrating Peptidic GRP78 Ligand-Conjugated Iron Oxide Magnetic Nanoparticles for Tumor-Targeted Doxorubicin Delivery and Imaging

“…Furthermore, in 2021, López-Muñoz et al prepared polymeric nanoparticles containing DOX. It was found that the DOX loading capacity (DLC) into the polymeric nanoparticle was variable, ranging from 0.54 to 6.91%, which is consistent with our DOX LC% (5.37%) …”

“…It was found that the DOX loading capacity (DLC) into the polymeric nanoparticle was variable, ranging from 0.54 to 6.91%, which is consistent with our DOX LC% (5.37%). 50 3.7. In Vitro DOX Release Study.…”

Aptamer-Based Smart Targeting and Spatial Trigger–Response Drug-Delivery Systems for Anticancer Therapy

“…The PNA nanogel core obtained a poly (N-isopropylacrylamide) (PNIPAM) group that shows thermo-sensitive phase transition properties [177,187,188]. The anticancer drug doxorubicin (DOX) was loaded in the PNA nanogel via electrostatic interaction [186,189,190]. This drug exhibited an accelerated release under low pH conditions, occurring during the endocytosis process in cancer cells [186,189,191,192].…”

“…Therefore, this developed nanoparticle exhibited the selective delivery of anticancer drugs spatiotemporally due to its active targeting ability and photo-induced release properties, in addition to photo-induced cancer tissue ablation for enabling effectively synergistic anticancer therapy. nanogel via electrostatic interaction [186,189,190]. This drug exhibited an accelerated release under low pH conditions, occurring during the endocytosis process in cancer cells [186,189,191,192].…”